Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $183
Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and raises the price target from $182 to $183.
A big bank analyst thinks Neurocrine stock is fairly priced right now, neither a great deal nor overpriced. They raised their price guess by one dollar, which is a tiny change that shows they still see the company the same way.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.